Data on the first experience of insulin degludec (Tresiba®) treatment for type 2 diabetes in daily clinical practice

Aim: The aim of this study was to evaluate the efficacy and safety of the new ultra-long-acting insulin degludec (Tresiba®) in the treatment of type 2 diabetes in routine clinical practice.Methods: This primary health care clinical observational study included 20 insulin-naïve type 2 diabetic patien...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lyudmila Alexandrovna Suplotova, Nikolay Valer'evich Plotnikov, Natal'ya Valer'yanovna Romanova, Larisa Nikolaevna Bel’chikova, Ekaterina Viktorovna Khieva, Marina Vladimirovna Shestakova
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2015
Materias:	type 2 diabetes mellitus insulin degludec glycaemic control hypoglycaemia quality of life Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/bb9f11fa3266492f955d458c1ee4ebc2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bb9f11fa3266492f955d458c1ee4ebc2
record_format	dspace
spelling	oai:doaj.org-article:bb9f11fa3266492f955d458c1ee4ebc22021-11-14T09:00:20ZData on the first experience of insulin degludec (Tresiba®) treatment for type 2 diabetes in daily clinical practice2072-03512072-037810.14341/DM7695https://doaj.org/article/bb9f11fa3266492f955d458c1ee4ebc22015-12-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/7695https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Aim: The aim of this study was to evaluate the efficacy and safety of the new ultra-long-acting insulin degludec (Tresiba®) in the treatment of type 2 diabetes in routine clinical practice.Methods: This primary health care clinical observational study included 20 insulin-naïve type 2 diabetic patients (mean age: 57.2 years, range: 54.4–61.5 years), who were inadequately controlled on maximum tolerated doses of oral antidiabetic drugs (OADs) and in whom baseline insulin therapy with ultra-long-acting insulin degludec was initiated. The duration of treatment was 6 months. The list of procedures met the ‘Standard of primary medical care in non-insulin-dependent diabetes mellitus’, as approved by the Ministry of Health of the Russian Federation (12.28.2012 №1581-n). Quality of life was assessed using the SF-36 questionnaire. All patients provided written consent before participating in the study.Results: In the outpatient setting, insulin degludec was well tolerated by all the patients. During the observational period, there were no events of symptomatic hypoglycaemia confirmed by self-measured plasma glucose (blood glucose level <3.9 mmol/l). At the end of the observational period, HbA1c, fasting plasma glucose level (FPG) and postprandial (2 h after a meal) plasma glucose level (PPG) had decreased. Despite the fact that most of the patients had poor baseline glycaemic control, after 6 months of degludec therapy, 45% of the participants achieved a target HbA1c of <7.0%, and 45% achieved a target HbA1c of <8.0%. Improved glycaemic control was associated with increased quality of life scores on both physical and mental health components.Conclusion: In this primary health care clinical observational study, the initiation of insulin degludec in type 2 diabetes patients with poor glycaemic control on OADs was associated with the achievement of effective glycaemic control. In addition, it had a good safety profile, and it improved quality of life scores and adherence to the treatment.Lyudmila Alexandrovna SuplotovaNikolay Valer'evich PlotnikovNatal'ya Valer'yanovna RomanovaLarisa Nikolaevna Bel’chikovaEkaterina Viktorovna KhievaMarina Vladimirovna ShestakovaEndocrinology Research Centrearticletype 2 diabetes mellitusinsulin degludecglycaemic controlhypoglycaemiaquality of lifeNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 18, Iss 4, Pp 92-98 (2015)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	type 2 diabetes mellitus insulin degludec glycaemic control hypoglycaemia quality of life Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	type 2 diabetes mellitus insulin degludec glycaemic control hypoglycaemia quality of life Nutritional diseases. Deficiency diseases RC620-627 Lyudmila Alexandrovna Suplotova Nikolay Valer'evich Plotnikov Natal'ya Valer'yanovna Romanova Larisa Nikolaevna Bel’chikova Ekaterina Viktorovna Khieva Marina Vladimirovna Shestakova Data on the first experience of insulin degludec (Tresiba®) treatment for type 2 diabetes in daily clinical practice
description	Aim: The aim of this study was to evaluate the efficacy and safety of the new ultra-long-acting insulin degludec (Tresiba®) in the treatment of type 2 diabetes in routine clinical practice.Methods: This primary health care clinical observational study included 20 insulin-naïve type 2 diabetic patients (mean age: 57.2 years, range: 54.4–61.5 years), who were inadequately controlled on maximum tolerated doses of oral antidiabetic drugs (OADs) and in whom baseline insulin therapy with ultra-long-acting insulin degludec was initiated. The duration of treatment was 6 months. The list of procedures met the ‘Standard of primary medical care in non-insulin-dependent diabetes mellitus’, as approved by the Ministry of Health of the Russian Federation (12.28.2012 №1581-n). Quality of life was assessed using the SF-36 questionnaire. All patients provided written consent before participating in the study.Results: In the outpatient setting, insulin degludec was well tolerated by all the patients. During the observational period, there were no events of symptomatic hypoglycaemia confirmed by self-measured plasma glucose (blood glucose level <3.9 mmol/l). At the end of the observational period, HbA1c, fasting plasma glucose level (FPG) and postprandial (2 h after a meal) plasma glucose level (PPG) had decreased. Despite the fact that most of the patients had poor baseline glycaemic control, after 6 months of degludec therapy, 45% of the participants achieved a target HbA1c of <7.0%, and 45% achieved a target HbA1c of <8.0%. Improved glycaemic control was associated with increased quality of life scores on both physical and mental health components.Conclusion: In this primary health care clinical observational study, the initiation of insulin degludec in type 2 diabetes patients with poor glycaemic control on OADs was associated with the achievement of effective glycaemic control. In addition, it had a good safety profile, and it improved quality of life scores and adherence to the treatment.
format	article
author	Lyudmila Alexandrovna Suplotova Nikolay Valer'evich Plotnikov Natal'ya Valer'yanovna Romanova Larisa Nikolaevna Bel’chikova Ekaterina Viktorovna Khieva Marina Vladimirovna Shestakova
author_facet	Lyudmila Alexandrovna Suplotova Nikolay Valer'evich Plotnikov Natal'ya Valer'yanovna Romanova Larisa Nikolaevna Bel’chikova Ekaterina Viktorovna Khieva Marina Vladimirovna Shestakova
author_sort	Lyudmila Alexandrovna Suplotova
title	Data on the first experience of insulin degludec (Tresiba®) treatment for type 2 diabetes in daily clinical practice
title_short	Data on the first experience of insulin degludec (Tresiba®) treatment for type 2 diabetes in daily clinical practice
title_full	Data on the first experience of insulin degludec (Tresiba®) treatment for type 2 diabetes in daily clinical practice
title_fullStr	Data on the first experience of insulin degludec (Tresiba®) treatment for type 2 diabetes in daily clinical practice
title_full_unstemmed	Data on the first experience of insulin degludec (Tresiba®) treatment for type 2 diabetes in daily clinical practice
title_sort	data on the first experience of insulin degludec (tresiba®) treatment for type 2 diabetes in daily clinical practice
publisher	Endocrinology Research Centre
publishDate	2015
url	https://doaj.org/article/bb9f11fa3266492f955d458c1ee4ebc2
work_keys_str_mv	AT lyudmilaalexandrovnasuplotova dataonthefirstexperienceofinsulindegludectresibatreatmentfortype2diabetesindailyclinicalpractice AT nikolayvalerevichplotnikov dataonthefirstexperienceofinsulindegludectresibatreatmentfortype2diabetesindailyclinicalpractice AT natalyavaleryanovnaromanova dataonthefirstexperienceofinsulindegludectresibatreatmentfortype2diabetesindailyclinicalpractice AT larisanikolaevnabelchikova dataonthefirstexperienceofinsulindegludectresibatreatmentfortype2diabetesindailyclinicalpractice AT ekaterinaviktorovnakhieva dataonthefirstexperienceofinsulindegludectresibatreatmentfortype2diabetesindailyclinicalpractice AT marinavladimirovnashestakova dataonthefirstexperienceofinsulindegludectresibatreatmentfortype2diabetesindailyclinicalpractice
_version_	1718429553689362432

Data on the first experience of insulin degludec (Tresiba®) treatment for type 2 diabetes in daily clinical practice

Ejemplares similares